Aav-gad for parkinson disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 May 2023: Trial started, NCT05894343
  2. 8 Jun 2023: Trial registered, NCT05894343

The trials

NCT05894343: Long-term Follow-up of Glutamic Acid Decarboxylase (GAD) Gene Transfer in Parkinson's Disease

State
Under way
Phase
Phase 1 and Phase 2
People
13 taking part
Started
19 May 2023
Primary completion
Oct 2029
Arms
Active treatment group
Results
None posted
  1. 19 May 2023: Trial started
  2. 8 Jun 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Gene therapy.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.